{"gene":"CETP","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2000,"finding":"The CETP gene is transcriptionally upregulated by dietary sterols via a DR4 (direct repeat-4) nuclear receptor binding element in its promoter (-384 to -399). LXR/RXR heterodimers bind this element and transactivate the CETP promoter in a sterol-responsive fashion, as demonstrated by promoter mutagenesis, gel retardation assays, and transgenic mouse studies with normal or mutated promoter sequences.","method":"Promoter-luciferase reporter assay, promoter mutagenesis, gel retardation/EMSA, transgenic mouse models with normal vs. mutated CETP promoter","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods (mutagenesis, EMSA, in vivo transgenic confirmation), single rigorous paper","pmids":["10683381"],"is_preprint":false},{"year":2010,"finding":"LXRα (but not LXRβ) is the essential subtype mediating LXR-dependent CETP transcriptional regulation. LXRα knockdown in HepG2 cells abolished LXR-agonist-induced CETP expression, and LXRα-deficient CETP transgenic mice failed to upregulate plasma CETP activity or hepatic CETP expression in response to synthetic LXR agonist, whereas LXRβ deficiency had no effect.","method":"siRNA knockdown in HepG2 cells, LXRα/LXRβ knockout CETP transgenic mice, CETP promoter-reporter assays","journal":"Atherosclerosis","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (cell knockdown, genetic KO in vivo, promoter assay) in single study","pmids":["20494359"],"is_preprint":false},{"year":2003,"finding":"Lipid transfer inhibitor protein (LTIP) modulates CETP-mediated lipid transfer in an HDL-subclass-specific manner: LTIP suppresses CETP activity on HDL2 and LDL while stimulating CETP activity on HDL3, resulting in a strong CETP preference for HDL3. TG enrichment of HDL2 further abolishes LTIP's stimulatory effect, keeping CETP activity on HDL2 low.","method":"In vitro CETP-mediated cholesteryl ester transfer assays with [3H]CE-labeled VLDL and various lipoprotein substrates; long-term mass transfer experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro transfer assays with multiple substrate combinations and mass transfer confirmation","pmids":["12907677"],"is_preprint":false},{"year":2006,"finding":"Adipose tissue is a major source of circulating CETP. Adipose-tissue-specific CETP transgenic mice with predominant adipose CETP mRNA expression showed readily detectable plasma CETP mass and activity, marked reductions in HDL cholesterol and apoA-I, and increases in non-HDL lipids and apoB, demonstrating that adipose-derived CETP makes a major contribution to circulating CETP and its lipoprotein-remodeling effects.","method":"Adipose-tissue-specific transgenic mouse model; plasma CETP mass and activity assays; lipoprotein analysis; adipocyte size and lipid content measurements; gene expression analysis","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — direct in vivo genetic model with multiple biochemical readouts","pmids":["16751623"],"is_preprint":false},{"year":1998,"finding":"Adipose tissue CETP mRNA levels are strongly correlated with plasma CETP concentrations (r=0.85, P<0.002) in humans, indicating that adipose tissue is a significant contributor to the plasma pool of CETP. CETP mRNA abundance in adipose tissue is negatively correlated with adipocyte size (TG-poor adipocytes express more CETP).","method":"Pericardiac adipose tissue CETP mRNA measurement (organ culture, correlation with plasma CETP); subcutaneous adipose tissue from healthy females; organ culture secretion assays","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 3 — correlational with ex vivo mRNA measurement; single study but two independent populations","pmids":["9712344"],"is_preprint":false},{"year":2006,"finding":"CETP expression in transgenic mice accelerates HDL cholesteryl ester (CE) fractional catabolic rate and enhances CE uptake by liver, adrenals, adipose tissue, and spleen. HDL fractions from both CETP transgenic and non-transgenic mice are cleared faster from plasma of CETP-expressing mice, indicating a direct role of CETP in accelerating tissue CE uptake independent of HDL particle origin. However, CETP expression does not alter hepatic VLDL-cholesterol/TG output or biliary lipid/fecal bile acid excretion.","method":"Radiolabeled HDL-CE kinetic studies in CETP transgenic vs. non-transgenic mice; hepatic VLDL secretion rate measurements; biliary lipid and fecal bile acid assays","journal":"Atherosclerosis","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo isotopic kinetic studies with multiple tissue readouts and mechanistic controls","pmids":["16806230"],"is_preprint":false},{"year":2009,"finding":"CETP expression in transgenic mice delays postprandial plasma clearance of triglyceride-rich lipoproteins by two mechanisms: (1) transferring TG to HDL and enriching remnant particles with CE, making them less susceptible to LPL-mediated lipolysis; and (2) reducing LPL expression and activity (~50% reduction in post-heparin plasma LPL activity and ~39% reduction in adipose LPL mRNA).","method":"Oral fat load postprandial TG curves; double-labeled chylomicron-like emulsion kinetics; VLDL secretion assay; post-heparin LPL activity; adipose LPL mRNA; CETP-Tg vs. non-Tg mice","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo transgenic model with multiple orthogonal mechanistic readouts (kinetics, enzyme activity, gene expression)","pmids":["19191759"],"is_preprint":false},{"year":2012,"finding":"CETP polymorphisms affecting mRNA splicing have functional consequences: an alternatively spliced isoform lacking exon 9 (Δ9) prevents CETP secretion in a dominant-negative manner. rs9930761 (intron 8) alters a key splicing branch point nucleotide and rs5883 (exon 9) alters an exonic splicing enhancer sequence, together increasing Δ9 isoform formation (10–48% of total CETP mRNA in human livers), independently raising HDL-C and influencing cardiovascular risk.","method":"Allelic CETP mRNA expression in 56 human livers; splice isoform measurements; SNP genotyping; functional association in Whitehall II (n=4745) and INVEST-GENE cohorts","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — direct human liver mRNA splicing data with mechanistic SNP-to-function mapping, replicated in two clinical cohorts","pmids":["22403620"],"is_preprint":false},{"year":2008,"finding":"Novel alternatively spliced CETP isoforms (skipping exon 9 sequences with insertion of Alu-derived in-frame exons) are not efficiently secreted and co-expression of them inhibits wild-type CETP secretion in a dominant-negative manner. Expression of all CETP variants (including wild-type) induces ER stress responses, suggesting CETP plays a role in modulating ER stress independent of its lipid transfer activity.","method":"Cell expression studies of splice variants; Western blot of secretion efficiency; ER stress gene induction assays","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — direct cell-based secretion and ER stress assays; single lab","pmids":["18509195"],"is_preprint":false},{"year":2008,"finding":"CETP variants found in Asian individuals (Y332, Q296, G442) are secreted less efficiently than wild-type protein but retain significant cholesteryl ester transfer activity in vitro, while P151 variant is not secreted and shows no transfer activity. A null splice variant causing protein truncation was found in Europeans on the same haplotype as in Asians, suggesting common origin.","method":"In vitro secretion efficiency by Western blot; fluorescent substrate CE transfer activity assay; exon resequencing","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 1–2 — in vitro reconstitution of secretion and enzymatic activity for multiple variants; single lab","pmids":["18468607"],"is_preprint":false},{"year":2008,"finding":"Novel CETP loss-of-function mutations (Q165X, R268X introducing premature stop codons; IVS15+2T>C abolishing a splice donor site) cause reduced CETP activity (38–60% reduction) and primary hyperalphalipoproteinemia in Italian subjects. Minigene analysis in COS-1 cells showed the IVS15+2T>C mutation causes exon 14–16 direct joining, producing a truncated 435-amino acid peptide.","method":"CETP gene sequencing; minigene splicing assay in COS-1 cells; plasma CETP activity assay","journal":"Atherosclerosis","confidence":"High","confidence_rationale":"Tier 1–2 — direct functional validation of mutations via minigene assay plus enzymatic activity measurement","pmids":["18926541"],"is_preprint":false},{"year":2016,"finding":"CETP expression in macrophages and endothelial cells lowers TLR4 expression and NF-κB activation, reducing LPS uptake, TLR4-dependent signaling, and IL-6 secretion. In transgenic mice, CETP expression improves survival in polymicrobial sepsis (CLP model) and reduces plasma IL-6. Recombinant human CETP added to wild-type macrophages recapitulates these effects.","method":"CETP transgenic mice CLP sepsis model; macrophage LPS stimulation with/without recombinant CETP; TLR4/NF-κB/IL-6 measurements; survival analysis","journal":"Mediators of inflammation","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo transgenic model plus in vitro recombinant protein experiments; single lab","pmids":["27293313"],"is_preprint":false},{"year":2021,"finding":"CETP expression in endothelial cells generates vascular oxidative stress and endothelial dysfunction. CETP transgenic mice show impaired acetylcholine-induced endothelium-dependent relaxation, increased superoxide and H2O2 production in aortas, and enhanced eNOS activation. Silencing CETP in human aortic endothelial cells reduces mitochondrial and NOX2-derived ROS, decreases ER stress markers, lowers TNFα, ICAM-1, and VCAM-1 expression, and reduces monocyte adhesion.","method":"Aortic ring relaxation assay in CETP transgenic mice; ROS measurement; eNOS activation assay; CETP siRNA knockdown in human endothelial cells; ER stress marker analysis; monocyte adhesion assay","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo transgenic model plus in vitro siRNA knockdown with multiple orthogonal mechanistic readouts; single lab","pmids":["33430172"],"is_preprint":false},{"year":2022,"finding":"CETP expression in macrophages reduces mitochondrial superoxide and H2O2 production, increases maximal mitochondrial respiration, promotes mitochondrial network elongation (increased mitofusin-2 and OPA1 expression), attenuates pro-inflammatory gene expression and phagocytic activity, reduces unesterified cholesterol accumulation under basal conditions and after oxidized-LDL exposure, and enhances HDL-mediated cholesterol efflux. CETP knockdown in THP1 cells increased unesterified cholesterol and abolished mitofusin-2 and TNFα effects.","method":"CETP transgenic mouse macrophages vs. non-transgenic; mitochondrial ROS/respiration assays; gene expression; CETP knockdown in THP1 cells; cholesterol efflux assay","journal":"Antioxidants (Basel, Switzerland)","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic model plus siRNA knockdown in human cells; multiple orthogonal readouts; single lab","pmids":["36139808"],"is_preprint":false},{"year":2014,"finding":"HDL isolated from carriers of CETP null mutations (genetic CETP deficiency) is significantly less effective than control HDL in stimulating nitric oxide (NO) production in endothelial cells due to reduced eNOS-activating capacity, likely because of reduced sphingosine-1-phosphate (S1P) content in structurally altered HDL particles. However, CETP-deficient HDL retains the ability to downregulate cytokine-induced VCAM-1 expression.","method":"HDL isolation from CETP-deficient human subjects; eNOS activation and NO production assays in cultured endothelial cells; VCAM-1 expression assays; S1P content analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional assay with human genetic CETP-deficient HDL; single study","pmids":["24830642"],"is_preprint":false},{"year":2021,"finding":"Using in vivo stable isotope tracer studies and compartmental modeling, CETP is secreted mainly in alpha1 and alpha2 HDL subfractions and remains in these sizes during circulation (unlike PLTP which transfers between HDL sizes). CETP metabolism on multiple HDL sizes was resolved by targeted mass spectrometry on the Orbitrap Fusion Lumos.","method":"In vivo stable isotope tracer kinetics; targeted mass spectrometry (Orbitrap Fusion Lumos); compartmental modeling of CETP on HDL subfractions from 6 participants","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 1–2 — in vivo tracer kinetics with MS-based compartmental modeling; small n but rigorous methodology","pmids":["33351780"],"is_preprint":false},{"year":2007,"finding":"Atorvastatin increases HDL-cholesterol in CETP-expressing (E3L.CETP) but not in non-CETP-expressing (E3L) mice by reducing hepatic CETP mRNA expression (-57%), lowering total plasma CETP mass (-29%) and CE transfer activity (-36%), thereby reducing CETP-dependent transfer of cholesterol from HDL to (V)LDL.","method":"Atorvastatin treatment of E3L and E3L.CETP transgenic mice; hepatic CETP mRNA quantification; plasma CETP mass and activity assays; lipoprotein cholesterol analysis","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 — controlled transgenic animal experiment with multiple biochemical readouts; single lab","pmids":["17868678"],"is_preprint":false},{"year":2015,"finding":"Anacetrapib reduces (V)LDL cholesterol by two CETP-related and CETP-independent mechanisms: (1) inhibition of CETP activity producing remodeled VLDL particles more susceptible to hepatic uptake; and (2) CETP-independent downregulation of hepatic PCSK9 expression (-28%), resulting in reduced plasma PCSK9 (-47%), increased hepatic LDL receptor content (+64%), and accelerated VLDL clearance. The PCSK9-lowering effect was confirmed in E3L mice lacking CETP.","method":"Anacetrapib treatment in E3L.CETP and E3L (non-CETP) transgenic mice; liver microarray; hepatic Pcsk9 and LDLr expression; plasma PCSK9 measurement; [14C]cholesteryl-oleate VLDL-mimicking particle clearance assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic dissection using CETP-expressing vs. CETP-null mice with multiple biochemical and in vivo clearance assays","pmids":["26342106"],"is_preprint":false},{"year":2018,"finding":"CETP inhibition with anacetrapib in high-fat-diet-fed CETP transgenic mice improves HDL functionality (reverse cholesterol transport, antioxidative capacity) but worsens anti-inflammatory HDL capacity, markedly alters the HDL proteome, and causes hepatic triglyceride accumulation and insulin resistance, revealing context-dependent (obese vs. lean) effects of CETP inhibition.","method":"Anacetrapib treatment in chow- and HFD-fed CETP transgenic mice; reverse cholesterol transport assay; HDL antioxidative and anti-inflammatory capacity assays; HDL proteomics; liver TG measurement; insulin resistance assessment","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal HDL functional assays in transgenic mice; single lab","pmids":["30213825"],"is_preprint":false},{"year":2015,"finding":"Novel CETP inhibitor K-312 decreases PCSK9 expression in human primary hepatocytes and HepG2 cells by a CETP-independent mechanism: it reduces active forms of SREBP-1 and SREBP-2 and decreases their occupancy on the sterol regulatory element of the PCSK9 promoter, as demonstrated by chromatin immunoprecipitation. CETP siRNA silencing did not abolish PCSK9 suppression by K-312.","method":"In vitro human primary hepatocyte and HepG2 cell assays; CETP siRNA knockdown; SREBP Western blot; chromatin immunoprecipitation (ChIP); PCSK9 protein measurement in rabbit blood by mass spectrometry","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 1–2 — ChIP assay plus siRNA knockdown controls establishing CETP-independent mechanism; single lab","pmids":["26015437"],"is_preprint":false},{"year":2005,"finding":"Apolipoprotein CI (apoCI) is a potent inhibitor of CETP specific activity in plasma. However, apoCI overexpression in CETP transgenic mice paradoxically increases total plasma CE transfer activity because the resulting hyperlipidemia activates LXR, upregulating hepatic CETP mRNA ~4-fold and CETP mass ~3-fold, demonstrating that LXR-mediated CETP gene induction can override pharmacological inhibition of specific CETP activity.","method":"CETPTg/apoCITg double transgenic mice; plasma CE transfer activity assays; hepatic CETP mRNA measurement; LXR-target gene expression (ABCG5, SREBP-1c)","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in vivo with enzymatic activity and gene expression readouts; single lab","pmids":["15339254"],"is_preprint":false}],"current_model":"CETP is a plasma glycoprotein (secreted primarily from liver and adipose tissue) that mediates bidirectional transfer of cholesteryl esters and triglycerides between HDL and apoB-containing lipoproteins (VLDL/LDL); its transcription is driven by LXRα/RXR via a DR4 promoter element in response to sterols; it preferentially acts on HDL3 (modulated by LTIP), delays TG-rich lipoprotein clearance partly by suppressing LPL, enhances hepatic HDL-CE uptake, and in endothelial cells and macrophages exerts direct effects on oxidative stress, ER homeostasis, and inflammatory signaling (TLR4/NF-κB pathway), while alternatively spliced Δ9 isoforms act as dominant-negative inhibitors of CETP secretion."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing that adipose tissue is a physiologically important source of plasma CETP resolved where the circulating protein originates beyond the liver.","evidence":"Correlation of adipose CETP mRNA with plasma CETP concentration (r=0.85) in two human cohorts using ex vivo organ culture","pmids":["9712344"],"confidence":"Medium","gaps":["Correlational design; no causal manipulation of adipose CETP in humans","Relative hepatic vs. adipose contribution not quantified in the same subjects"]},{"year":2000,"claim":"Identification of the DR4 element and LXR/RXR-dependent sterol-responsive transcription of CETP established the core transcriptional control mechanism linking dietary cholesterol to plasma CETP levels.","evidence":"Promoter-luciferase mutagenesis, EMSA, and transgenic mice with normal vs. mutated CETP promoter","pmids":["10683381"],"confidence":"High","gaps":["Other transcription factors acting on the CETP promoter not characterized","Tissue-specific differences in LXR-dependent regulation not resolved"]},{"year":2003,"claim":"Demonstrating that LTIP modulates CETP substrate specificity—stimulating CE transfer from HDL3 while suppressing it from HDL2—explained the observed in vivo HDL-subclass selectivity of CETP.","evidence":"Reconstituted in vitro CE transfer assays with radiolabeled substrates and multiple lipoprotein fractions","pmids":["12907677"],"confidence":"High","gaps":["In vivo relevance of LTIP modulation not tested in animal models","Structural basis of LTIP–CETP interaction unknown"]},{"year":2005,"claim":"The finding that apoCI-induced hyperlipidemia overrides apoCI's direct CETP inhibition via LXR-mediated CETP gene induction revealed a feedback loop in which substrate accumulation amplifies CETP expression.","evidence":"Double-transgenic (CETPTg/apoCITg) mice with hepatic gene expression and plasma CE transfer activity measurements","pmids":["15339254"],"confidence":"Medium","gaps":["Precise LXR ligand(s) generated by apoCI-induced hyperlipidemia not identified","Relevance to human apoCI–CETP axis not confirmed"]},{"year":2006,"claim":"Adipose-specific CETP transgenic mice proved causally that adipose-derived CETP contributes substantially to circulating CETP mass and produces systemic lipoprotein remodeling (reduced HDL-C, increased non-HDL cholesterol).","evidence":"Adipose-tissue-specific transgenic mouse model with plasma CETP mass/activity and lipoprotein profiling","pmids":["16751623"],"confidence":"High","gaps":["Quantitative contribution of adipose vs. hepatic CETP in humans remains unresolved"]},{"year":2006,"claim":"Radiolabeled HDL-CE kinetic studies in CETP transgenic mice demonstrated that CETP accelerates hepatic (and other tissue) CE uptake without altering VLDL secretion or biliary excretion, defining the catabolic arm of CETP's effect on HDL.","evidence":"In vivo isotopic HDL-CE kinetics in CETP transgenic vs. non-transgenic mice with tissue uptake measurements","pmids":["16806230"],"confidence":"High","gaps":["Receptor(s) mediating enhanced hepatic CE uptake in the presence of CETP not identified","Biliary cholesterol secretion pathway may differ in humans"]},{"year":2008,"claim":"Discovery and functional characterization of alternatively spliced CETP isoforms (Δ9 and Alu-exon insertions) that are secretion-incompetent and act as dominant-negative inhibitors of wild-type CETP secretion revealed a post-transcriptional layer of CETP regulation and linked CETP expression to ER stress.","evidence":"Cell-based secretion assays, Western blot, ER stress gene induction; variant activity reconstitution; human liver mRNA quantification","pmids":["18509195","22403620","18468607"],"confidence":"High","gaps":["Physiological triggers that shift the splicing ratio in vivo are unknown","ER stress induction mechanism by CETP variants not elucidated"]},{"year":2008,"claim":"Identification of loss-of-function CETP mutations (Q165X, R268X, IVS15+2T>C) causing hyperalphalipoproteinemia in Italian subjects, with functional validation by minigene assays, established that CETP deficiency is a Mendelian cause of elevated HDL-C in Europeans as well as Asians.","evidence":"CETP gene sequencing, minigene splicing assay in COS-1 cells, plasma CETP activity measurement","pmids":["18926541"],"confidence":"High","gaps":["Cardiovascular outcome in European CETP-deficient subjects not resolved","Compound heterozygote phenotypes not characterized"]},{"year":2009,"claim":"Showing that CETP delays postprandial TG-rich lipoprotein clearance both by remodeling remnant composition and by suppressing LPL expression/activity explained CETP's proatherogenic role beyond HDL lowering.","evidence":"Oral fat load kinetics, double-labeled chylomicron-like emulsion clearance, post-heparin LPL activity, and adipose LPL mRNA in CETP transgenic mice","pmids":["19191759"],"confidence":"High","gaps":["Mechanism by which CETP reduces LPL transcription is not defined","Human postprandial studies with CETP inhibitors needed for translation"]},{"year":2010,"claim":"Establishing that LXRα—not LXRβ—is the obligate mediator of sterol-responsive CETP transcription refined the transcriptional model and identified a druggable regulatory node.","evidence":"siRNA knockdown in HepG2 cells plus LXRα-knockout CETP transgenic mice","pmids":["20494359"],"confidence":"High","gaps":["Whether LXRα-selective agonists differentially regulate CETP in human liver is untested"]},{"year":2015,"claim":"Dissection of anacetrapib's dual mechanism—CETP-dependent VLDL remodeling plus CETP-independent PCSK9/LDL-receptor regulation—revealed that pharmacological CETP inhibitors have off-target effects on hepatic cholesterol homeostasis.","evidence":"Anacetrapib treatment in E3L.CETP and E3L (non-CETP) transgenic mice; liver microarray; ChIP for SREBP on PCSK9 promoter; VLDL clearance assays","pmids":["26342106","26015437"],"confidence":"High","gaps":["CETP-independent PCSK9-lowering mechanism of anacetrapib not fully resolved at the molecular level","Translation to human hepatocytes awaits confirmation"]},{"year":2016,"claim":"Demonstrating that CETP lowers TLR4 expression and NF-κB activation in macrophages and endothelial cells, improving sepsis survival, uncovered a direct anti-inflammatory function independent of lipoprotein remodeling.","evidence":"CETP transgenic mice in CLP sepsis model; recombinant CETP added to macrophages; TLR4/NF-κB/IL-6 measurements","pmids":["27293313"],"confidence":"Medium","gaps":["Mechanism by which CETP reduces TLR4 expression is unknown","Single-lab finding; not independently replicated"]},{"year":2021,"claim":"In vivo stable-isotope tracer kinetics resolved that CETP is secreted into and circulates predominantly on alpha1 and alpha2 HDL subfractions, providing a biophysical framework for its site of action in lipoprotein remodeling.","evidence":"Stable isotope tracer kinetics with targeted mass spectrometry and compartmental modeling in 6 human participants","pmids":["33351780"],"confidence":"Medium","gaps":["Small sample size (n=6)","Whether CETP's HDL subfraction distribution changes in dyslipidemia is unknown"]},{"year":2022,"claim":"Showing that macrophage CETP expression reduces mitochondrial ROS, promotes mitochondrial fusion (via mitofusin-2/OPA1), and enhances HDL-mediated cholesterol efflux extended CETP's intracellular functions to mitochondrial dynamics and oxidative stress regulation.","evidence":"CETP transgenic mouse macrophages and CETP-knockdown THP1 cells; mitochondrial respiration/ROS assays; cholesterol efflux; gene expression","pmids":["36139808"],"confidence":"Medium","gaps":["Mechanism linking CETP to mitofusin-2 induction unknown","Single-lab finding; no independent replication","Physiological relevance of macrophage-endogenous CETP expression in humans unclear"]},{"year":null,"claim":"Key unresolved questions include the structural basis of CETP's interaction with specific HDL subclasses and LTIP, the molecular mechanism by which CETP suppresses LPL and TLR4 expression, and whether the intracellular (ER stress, mitochondrial) functions of CETP are physiologically significant in humans.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of CETP bound to HDL or LTIP","Mechanism of LPL transcriptional suppression by CETP undefined","Intracellular CETP functions tested only in transgenic models and cell lines"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,5,6]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[2,5,9]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,4,5,15]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[8,12]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[2,5,6,17]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[2,5,6,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,20]}],"complexes":[],"partners":["LXRA","RXRA","APOC1","LPL","APOA1","MFN2"],"other_free_text":[]},"mechanistic_narrative":"CETP is a secreted plasma glycoprotein that mediates the bidirectional transfer of cholesteryl esters and triglycerides between HDL and apoB-containing lipoproteins (VLDL/LDL), thereby serving as a central regulator of plasma lipoprotein remodeling, HDL metabolism, and reverse cholesterol transport. Transcription of CETP is driven by LXRα/RXR heterodimers binding a DR4 element in the promoter in response to sterols, with LXRα—not LXRβ—being the essential subtype [PMID:10683381, PMID:20494359]; adipose tissue and liver are the principal sources of circulating CETP [PMID:16751623, PMID:9712344]. Functionally, CETP accelerates hepatic HDL-cholesteryl ester uptake, delays postprandial triglyceride-rich lipoprotein clearance in part by suppressing LPL expression, and preferentially acts on HDL3 through modulation by lipid transfer inhibitor protein (LTIP) [PMID:16806230, PMID:19191759, PMID:12907677]. Loss-of-function mutations (including premature stop codons and splice-site variants) cause primary hyperalphalipoproteinemia, and alternatively spliced Δ9 isoforms act as dominant-negative inhibitors of CETP secretion, linking common intronic/exonic polymorphisms to elevated HDL-C [PMID:18926541, PMID:22403620]."},"prefetch_data":{"uniprot":{"accession":"P11597","full_name":"Cholesteryl ester transfer protein","aliases":["Lipid transfer protein I"],"length_aa":493,"mass_kda":54.8,"function":"Involved in the transfer of neutral lipids, including cholesteryl ester and triglyceride, among lipoprotein particles. Allows the net movement of cholesteryl ester from high density lipoproteins/HDL to triglyceride-rich very low density lipoproteins/VLDL, and the equimolar transport of triglyceride from VLDL to HDL (PubMed:24293641, PubMed:3281933, PubMed:3600759). Regulates the reverse cholesterol transport, by which excess cholesterol is removed from peripheral tissues and returned to the liver for elimination (PubMed:17237796)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P11597/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CETP","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CETP","total_profiled":1310},"omim":[{"mim_id":"617074","title":"SMITH-MAGENIS SYNDROME CHROMOSOME REGION, CANDIDATE GENE 8; SMCR8","url":"https://www.omim.org/entry/617074"},{"mim_id":"614110","title":"BPI FOLD-CONTAINING PROTEIN, FAMILY B, MEMBER 6; BPIFB6","url":"https://www.omim.org/entry/614110"},{"mim_id":"614109","title":"BPI FOLD-CONTAINING PROTEIN, FAMILY C; BPIFC","url":"https://www.omim.org/entry/614109"},{"mim_id":"614108","title":"BPI FOLD-CONTAINING PROTEIN, FAMILY B, MEMBER 2; BPIFB2","url":"https://www.omim.org/entry/614108"},{"mim_id":"609708","title":"LIPOPROTEIN LIPASE; LPL","url":"https://www.omim.org/entry/609708"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":31.4},{"tissue":"liver","ntpm":40.2},{"tissue":"lymphoid tissue","ntpm":56.2},{"tissue":"placenta","ntpm":34.0}],"url":"https://www.proteinatlas.org/search/CETP"},"hgnc":{"alias_symbol":["BPIFF"],"prev_symbol":[]},"alphafold":{"accession":"P11597","domains":[{"cath_id":"3.15.10.10","chopping":"34-220","consensus_level":"medium","plddt":91.8213,"start":34,"end":220},{"cath_id":"3.15.20.10","chopping":"227-478","consensus_level":"medium","plddt":94.9965,"start":227,"end":478}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11597","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11597-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11597-F1-predicted_aligned_error_v6.png","plddt_mean":91.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CETP","jax_strain_url":"https://www.jax.org/strain/search?query=CETP"},"sequence":{"accession":"P11597","fasta_url":"https://rest.uniprot.org/uniprotkb/P11597.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11597/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11597"}},"corpus_meta":[{"pmid":"10683381","id":"PMC_10683381","title":"Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element.","date":"2000","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10683381","citation_count":285,"is_preprint":false},{"pmid":"28846118","id":"PMC_28846118","title":"Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.","date":"2017","source":"JAMA","url":"https://pubmed.ncbi.nlm.nih.gov/28846118","citation_count":250,"is_preprint":false},{"pmid":"29018035","id":"PMC_29018035","title":"Trials and Tribulations of CETP Inhibitors.","date":"2017","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/29018035","citation_count":221,"is_preprint":false},{"pmid":"15342674","id":"PMC_15342674","title":"A review of CETP and its relation to atherosclerosis.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15342674","citation_count":204,"is_preprint":false},{"pmid":"23083790","id":"PMC_23083790","title":"Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.","date":"2012","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23083790","citation_count":129,"is_preprint":false},{"pmid":"12860257","id":"PMC_12860257","title":"The safety and immunogenicity of a CETP vaccine in healthy adults.","date":"2003","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/12860257","citation_count":108,"is_preprint":false},{"pmid":"34561430","id":"PMC_34561430","title":"Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34561430","citation_count":95,"is_preprint":false},{"pmid":"17868678","id":"PMC_17868678","title":"Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.","date":"2007","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/17868678","citation_count":67,"is_preprint":false},{"pmid":"29141072","id":"PMC_29141072","title":"Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults.","date":"2018","source":"JAMA cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/29141072","citation_count":61,"is_preprint":false},{"pmid":"22679067","id":"PMC_22679067","title":"New molecular insights into CETP structure and function: a review.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22679067","citation_count":60,"is_preprint":false},{"pmid":"16439711","id":"PMC_16439711","title":"Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.","date":"2006","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16439711","citation_count":57,"is_preprint":false},{"pmid":"23658137","id":"PMC_23658137","title":"Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.","date":"2013","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/23658137","citation_count":57,"is_preprint":false},{"pmid":"15243211","id":"PMC_15243211","title":"CETP gene variation: relation to lipid parameters and cardiovascular risk.","date":"2004","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/15243211","citation_count":56,"is_preprint":false},{"pmid":"26997876","id":"PMC_26997876","title":"CETP Inhibition: Past Failures and Future Hopes.","date":"2016","source":"Clinical Medicine Insights. Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26997876","citation_count":56,"is_preprint":false},{"pmid":"22403620","id":"PMC_22403620","title":"Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22403620","citation_count":54,"is_preprint":false},{"pmid":"31389129","id":"PMC_31389129","title":"Akkermansia muciniphila Exerts Lipid-Lowering and Immunomodulatory Effects without Affecting Neointima Formation in Hyperlipidemic APOE*3-Leiden.CETP Mice.","date":"2019","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/31389129","citation_count":53,"is_preprint":false},{"pmid":"10924728","id":"PMC_10924728","title":"Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol.","date":"2000","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/10924728","citation_count":51,"is_preprint":false},{"pmid":"27827461","id":"PMC_27827461","title":"Association and interaction of APOA5, BUD13, CETP, LIPA and health-related behavior with metabolic syndrome in a Taiwanese population.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27827461","citation_count":49,"is_preprint":false},{"pmid":"22130116","id":"PMC_22130116","title":"Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.","date":"2011","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22130116","citation_count":49,"is_preprint":false},{"pmid":"29523487","id":"PMC_29523487","title":"Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk.","date":"2018","source":"Diabetes & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29523487","citation_count":47,"is_preprint":false},{"pmid":"35921096","id":"PMC_35921096","title":"Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.","date":"2022","source":"JAMA cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/35921096","citation_count":46,"is_preprint":false},{"pmid":"15888337","id":"PMC_15888337","title":"Cholesteryl ester transfer protein (CETP) I405V polymorphism and longevity in Italian centenarians.","date":"2005","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/15888337","citation_count":45,"is_preprint":false},{"pmid":"28980665","id":"PMC_28980665","title":"Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease.","date":"2017","source":"Nature reviews. Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28980665","citation_count":45,"is_preprint":false},{"pmid":"24373179","id":"PMC_24373179","title":"APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.","date":"2014","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24373179","citation_count":45,"is_preprint":false},{"pmid":"9712344","id":"PMC_9712344","title":"Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man.","date":"1998","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/9712344","citation_count":45,"is_preprint":false},{"pmid":"24628035","id":"PMC_24628035","title":"Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.","date":"2014","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24628035","citation_count":44,"is_preprint":false},{"pmid":"12907677","id":"PMC_12907677","title":"Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP).","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12907677","citation_count":44,"is_preprint":false},{"pmid":"17272756","id":"PMC_17272756","title":"Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17272756","citation_count":43,"is_preprint":false},{"pmid":"25410905","id":"PMC_25410905","title":"Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.","date":"2014","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/25410905","citation_count":43,"is_preprint":false},{"pmid":"26503844","id":"PMC_26503844","title":"CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26503844","citation_count":42,"is_preprint":false},{"pmid":"38133847","id":"PMC_38133847","title":"Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.","date":"2023","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/38133847","citation_count":41,"is_preprint":false},{"pmid":"16002074","id":"PMC_16002074","title":"The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia.","date":"2005","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16002074","citation_count":41,"is_preprint":false},{"pmid":"11730826","id":"PMC_11730826","title":"Influence of CETP gene variation on plasma lipid levels and coronary heart disease: a survey in Taiwan.","date":"2001","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11730826","citation_count":40,"is_preprint":false},{"pmid":"7889597","id":"PMC_7889597","title":"Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP).","date":"1994","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7889597","citation_count":40,"is_preprint":false},{"pmid":"12032161","id":"PMC_12032161","title":"Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12032161","citation_count":39,"is_preprint":false},{"pmid":"18414186","id":"PMC_18414186","title":"HDL metabolism and CETP inhibition.","date":"2008","source":"Cardiology in review","url":"https://pubmed.ncbi.nlm.nih.gov/18414186","citation_count":38,"is_preprint":false},{"pmid":"24283500","id":"PMC_24283500","title":"CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population.","date":"2013","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/24283500","citation_count":38,"is_preprint":false},{"pmid":"15529021","id":"PMC_15529021","title":"Role of CETP inhibitors in the treatment of dyslipidemia.","date":"2004","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/15529021","citation_count":37,"is_preprint":false},{"pmid":"2567644","id":"PMC_2567644","title":"\"Variability gene\" effect of cholesteryl ester transfer protein (CETP) genes.","date":"1989","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2567644","citation_count":36,"is_preprint":false},{"pmid":"26015437","id":"PMC_26015437","title":"New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.","date":"2015","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26015437","citation_count":36,"is_preprint":false},{"pmid":"35441656","id":"PMC_35441656","title":"The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis.","date":"2022","source":"European heart journal. Cardiovascular pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/35441656","citation_count":35,"is_preprint":false},{"pmid":"19150509","id":"PMC_19150509","title":"PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19150509","citation_count":35,"is_preprint":false},{"pmid":"27717122","id":"PMC_27717122","title":"Genetic variants in CETP increase risk of intracerebral hemorrhage.","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27717122","citation_count":34,"is_preprint":false},{"pmid":"16603720","id":"PMC_16603720","title":"Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16603720","citation_count":34,"is_preprint":false},{"pmid":"27293313","id":"PMC_27293313","title":"CETP Lowers TLR4 Expression Which Attenuates the Inflammatory Response Induced by LPS and Polymicrobial Sepsis.","date":"2016","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27293313","citation_count":33,"is_preprint":false},{"pmid":"16751623","id":"PMC_16751623","title":"Adipose tissue-specific CETP expression in mice: impact on plasma lipoprotein metabolism.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16751623","citation_count":33,"is_preprint":false},{"pmid":"17121756","id":"PMC_17121756","title":"Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.","date":"2006","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/17121756","citation_count":33,"is_preprint":false},{"pmid":"32033866","id":"PMC_32033866","title":"A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?","date":"2020","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/32033866","citation_count":32,"is_preprint":false},{"pmid":"30213825","id":"PMC_30213825","title":"CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet.","date":"2018","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/30213825","citation_count":32,"is_preprint":false},{"pmid":"26985312","id":"PMC_26985312","title":"Discovery of Novel Indoline Cholesterol Ester Transfer Protein Inhibitors (CETP) through a Structure-Guided Approach.","date":"2016","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/26985312","citation_count":31,"is_preprint":false},{"pmid":"20494359","id":"PMC_20494359","title":"LXRalpha regulates human CETP expression in vitro and in transgenic mice.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/20494359","citation_count":31,"is_preprint":false},{"pmid":"19522058","id":"PMC_19522058","title":"The end of the road for CETP inhibitors after torcetrapib?","date":"2009","source":"Current opinion in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19522058","citation_count":31,"is_preprint":false},{"pmid":"30420679","id":"PMC_30420679","title":"Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile.","date":"2018","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/30420679","citation_count":31,"is_preprint":false},{"pmid":"11181754","id":"PMC_11181754","title":"ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.","date":"2001","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/11181754","citation_count":31,"is_preprint":false},{"pmid":"29558025","id":"PMC_29558025","title":"Plasma lipid transfer proteins: The role of PLTP and CETP in atherogenesis.","date":"2018","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/29558025","citation_count":29,"is_preprint":false},{"pmid":"24830642","id":"PMC_24830642","title":"eNOS activation by HDL is impaired in genetic CETP deficiency.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24830642","citation_count":29,"is_preprint":false},{"pmid":"24659026","id":"PMC_24659026","title":"Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians.","date":"2014","source":"European journal of preventive cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/24659026","citation_count":29,"is_preprint":false},{"pmid":"21122682","id":"PMC_21122682","title":"Update on CETP inhibition.","date":"2010","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/21122682","citation_count":28,"is_preprint":false},{"pmid":"26342106","id":"PMC_26342106","title":"Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26342106","citation_count":27,"is_preprint":false},{"pmid":"19491422","id":"PMC_19491422","title":"Taq1B polymorphism of cholesteryl ester transfer protein (CETP) gene in primary combined hyperlipidaemia.","date":"2009","source":"The Indian journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/19491422","citation_count":26,"is_preprint":false},{"pmid":"33430172","id":"PMC_33430172","title":"The Presence of Cholesteryl Ester Transfer Protein (CETP) in Endothelial Cells Generates Vascular Oxidative Stress and Endothelial Dysfunction.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/33430172","citation_count":25,"is_preprint":false},{"pmid":"17108362","id":"PMC_17108362","title":"High-density genotyping and functional SNP localization in the CETP gene.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17108362","citation_count":25,"is_preprint":false},{"pmid":"30657992","id":"PMC_30657992","title":"Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice.","date":"2019","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30657992","citation_count":25,"is_preprint":false},{"pmid":"23166663","id":"PMC_23166663","title":"Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23166663","citation_count":25,"is_preprint":false},{"pmid":"24997672","id":"PMC_24997672","title":"Serum cholesterol and variant in cholesterol-related gene CETP predict white matter microstructure.","date":"2014","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/24997672","citation_count":24,"is_preprint":false},{"pmid":"18670196","id":"PMC_18670196","title":"Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice.","date":"2009","source":"Human vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/18670196","citation_count":24,"is_preprint":false},{"pmid":"11140626","id":"PMC_11140626","title":"Genetic polymorphisms and activity of cholesterol ester transfer protein (CETP): should we be measuring them?","date":"2000","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11140626","citation_count":24,"is_preprint":false},{"pmid":"17196207","id":"PMC_17196207","title":"Effects of cholesterol ester transfer protein (CETP) gene on adiposity in response to long-term overfeeding.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/17196207","citation_count":24,"is_preprint":false},{"pmid":"30273401","id":"PMC_30273401","title":"Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30273401","citation_count":24,"is_preprint":false},{"pmid":"28126828","id":"PMC_28126828","title":"CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.","date":"2017","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28126828","citation_count":24,"is_preprint":false},{"pmid":"35098451","id":"PMC_35098451","title":"A Nutrigenetic Update on CETP Gene-Diet Interactions on Lipid-Related Outcomes.","date":"2022","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/35098451","citation_count":23,"is_preprint":false},{"pmid":"28099220","id":"PMC_28099220","title":"Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.","date":"2017","source":"Cardiology in review","url":"https://pubmed.ncbi.nlm.nih.gov/28099220","citation_count":23,"is_preprint":false},{"pmid":"18637884","id":"PMC_18637884","title":"Cholesteryl ester transfer protein (CETP) genetic variation and early onset of non-fatal myocardial infarction.","date":"2008","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18637884","citation_count":23,"is_preprint":false},{"pmid":"18926541","id":"PMC_18926541","title":"Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18926541","citation_count":23,"is_preprint":false},{"pmid":"36139808","id":"PMC_36139808","title":"Novel Role of CETP in Macrophages: Reduction of Mitochondrial Oxidants Production and Modulation of Cell Immune-Metabolic Profile.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36139808","citation_count":22,"is_preprint":false},{"pmid":"16806230","id":"PMC_16806230","title":"CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion.","date":"2006","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16806230","citation_count":22,"is_preprint":false},{"pmid":"19835569","id":"PMC_19835569","title":"Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs.","date":"2009","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19835569","citation_count":20,"is_preprint":false},{"pmid":"23317399","id":"PMC_23317399","title":"The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular disease.","date":"2013","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/23317399","citation_count":20,"is_preprint":false},{"pmid":"18929230","id":"PMC_18929230","title":"Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?","date":"2008","source":"Cardiology clinics","url":"https://pubmed.ncbi.nlm.nih.gov/18929230","citation_count":19,"is_preprint":false},{"pmid":"30178218","id":"PMC_30178218","title":"Relationship between CETP gene polymorphisms with coronary artery disease in Polish population.","date":"2018","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30178218","citation_count":19,"is_preprint":false},{"pmid":"15339254","id":"PMC_15339254","title":"Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15339254","citation_count":19,"is_preprint":false},{"pmid":"28918250","id":"PMC_28918250","title":"Associations of cholesteryl ester transfer protein (CETP) gene variants with predisposition to age-related macular degeneration.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28918250","citation_count":18,"is_preprint":false},{"pmid":"18509195","id":"PMC_18509195","title":"Expression of CETP and of splice variants induces the same level of ER stress despite secretion efficiency differences.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18509195","citation_count":18,"is_preprint":false},{"pmid":"19191759","id":"PMC_19191759","title":"Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19191759","citation_count":18,"is_preprint":false},{"pmid":"37379656","id":"PMC_37379656","title":"Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice.","date":"2023","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37379656","citation_count":17,"is_preprint":false},{"pmid":"28961179","id":"PMC_28961179","title":"Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?","date":"2017","source":"Diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/28961179","citation_count":17,"is_preprint":false},{"pmid":"20581105","id":"PMC_20581105","title":"Gene-environment interactions of CETP gene variation in a high cardiovascular risk Mediterranean population.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/20581105","citation_count":17,"is_preprint":false},{"pmid":"25143122","id":"PMC_25143122","title":"Production of a plant-derived immunogenic protein targeting ApoB100 and CETP: toward a plant-based atherosclerosis vaccine.","date":"2014","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/25143122","citation_count":17,"is_preprint":false},{"pmid":"7474298","id":"PMC_7474298","title":"CETP and LCAT activities are unrelated to smoking and moderate alcohol consumption in healthy normolipidemic men.","date":"1995","source":"Japanese circulation journal","url":"https://pubmed.ncbi.nlm.nih.gov/7474298","citation_count":17,"is_preprint":false},{"pmid":"39150671","id":"PMC_39150671","title":"Obicetrapib-the Rebirth of CETP Inhibitors?","date":"2024","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/39150671","citation_count":16,"is_preprint":false},{"pmid":"29424255","id":"PMC_29424255","title":"The therapeutic potential of CETP inhibitors: a patent review.","date":"2018","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/29424255","citation_count":16,"is_preprint":false},{"pmid":"25105518","id":"PMC_25105518","title":"Relationships between CETP genetic polymorphisms and Alzheimer's disease risk: a meta-analysis.","date":"2014","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25105518","citation_count":16,"is_preprint":false},{"pmid":"33351780","id":"PMC_33351780","title":"Metabolism of PLTP, CETP, and LCAT on multiple HDL sizes using the Orbitrap Fusion Lumos.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33351780","citation_count":16,"is_preprint":false},{"pmid":"19519458","id":"PMC_19519458","title":"Cholesteryl ester transfer protein (CETP) inhibitors.","date":"2009","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19519458","citation_count":16,"is_preprint":false},{"pmid":"34354158","id":"PMC_34354158","title":"Interaction between CETP polymorphism and dietary insulin index and load in relation to cardiovascular risk factors in diabetic adults.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34354158","citation_count":15,"is_preprint":false},{"pmid":"36345867","id":"PMC_36345867","title":"Can we revive CETP-inhibitors for the prevention of cardiovascular disease?","date":"2022","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/36345867","citation_count":14,"is_preprint":false},{"pmid":"19428034","id":"PMC_19428034","title":"Two novel mutations and functional analyses of the CETP and LIPC genes underlying severe hyperalphalipoproteinemia.","date":"2009","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/19428034","citation_count":14,"is_preprint":false},{"pmid":"28629169","id":"PMC_28629169","title":"Association between Six CETP Polymorphisms and Metabolic Syndrome in Uyghur Adults from Xinjiang, China.","date":"2017","source":"International journal of environmental research and public health","url":"https://pubmed.ncbi.nlm.nih.gov/28629169","citation_count":14,"is_preprint":false},{"pmid":"18468607","id":"PMC_18468607","title":"Frequency and function of CETP variants among individuals of Asian ancestry.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18468607","citation_count":14,"is_preprint":false},{"pmid":"33766515","id":"PMC_33766515","title":"Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice.","date":"2021","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/33766515","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53035,"output_tokens":5765,"usd":0.12279},"stage2":{"model":"claude-opus-4-6","input_tokens":9342,"output_tokens":3451,"usd":0.199478},"total_usd":0.322268,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"The CETP gene is transcriptionally upregulated by dietary sterols via a DR4 (direct repeat-4) nuclear receptor binding element in its promoter (-384 to -399). LXR/RXR heterodimers bind this element and transactivate the CETP promoter in a sterol-responsive fashion, as demonstrated by promoter mutagenesis, gel retardation assays, and transgenic mouse studies with normal or mutated promoter sequences.\",\n      \"method\": \"Promoter-luciferase reporter assay, promoter mutagenesis, gel retardation/EMSA, transgenic mouse models with normal vs. mutated CETP promoter\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (mutagenesis, EMSA, in vivo transgenic confirmation), single rigorous paper\",\n      \"pmids\": [\"10683381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LXRα (but not LXRβ) is the essential subtype mediating LXR-dependent CETP transcriptional regulation. LXRα knockdown in HepG2 cells abolished LXR-agonist-induced CETP expression, and LXRα-deficient CETP transgenic mice failed to upregulate plasma CETP activity or hepatic CETP expression in response to synthetic LXR agonist, whereas LXRβ deficiency had no effect.\",\n      \"method\": \"siRNA knockdown in HepG2 cells, LXRα/LXRβ knockout CETP transgenic mice, CETP promoter-reporter assays\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (cell knockdown, genetic KO in vivo, promoter assay) in single study\",\n      \"pmids\": [\"20494359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Lipid transfer inhibitor protein (LTIP) modulates CETP-mediated lipid transfer in an HDL-subclass-specific manner: LTIP suppresses CETP activity on HDL2 and LDL while stimulating CETP activity on HDL3, resulting in a strong CETP preference for HDL3. TG enrichment of HDL2 further abolishes LTIP's stimulatory effect, keeping CETP activity on HDL2 low.\",\n      \"method\": \"In vitro CETP-mediated cholesteryl ester transfer assays with [3H]CE-labeled VLDL and various lipoprotein substrates; long-term mass transfer experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro transfer assays with multiple substrate combinations and mass transfer confirmation\",\n      \"pmids\": [\"12907677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Adipose tissue is a major source of circulating CETP. Adipose-tissue-specific CETP transgenic mice with predominant adipose CETP mRNA expression showed readily detectable plasma CETP mass and activity, marked reductions in HDL cholesterol and apoA-I, and increases in non-HDL lipids and apoB, demonstrating that adipose-derived CETP makes a major contribution to circulating CETP and its lipoprotein-remodeling effects.\",\n      \"method\": \"Adipose-tissue-specific transgenic mouse model; plasma CETP mass and activity assays; lipoprotein analysis; adipocyte size and lipid content measurements; gene expression analysis\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vivo genetic model with multiple biochemical readouts\",\n      \"pmids\": [\"16751623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Adipose tissue CETP mRNA levels are strongly correlated with plasma CETP concentrations (r=0.85, P<0.002) in humans, indicating that adipose tissue is a significant contributor to the plasma pool of CETP. CETP mRNA abundance in adipose tissue is negatively correlated with adipocyte size (TG-poor adipocytes express more CETP).\",\n      \"method\": \"Pericardiac adipose tissue CETP mRNA measurement (organ culture, correlation with plasma CETP); subcutaneous adipose tissue from healthy females; organ culture secretion assays\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — correlational with ex vivo mRNA measurement; single study but two independent populations\",\n      \"pmids\": [\"9712344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CETP expression in transgenic mice accelerates HDL cholesteryl ester (CE) fractional catabolic rate and enhances CE uptake by liver, adrenals, adipose tissue, and spleen. HDL fractions from both CETP transgenic and non-transgenic mice are cleared faster from plasma of CETP-expressing mice, indicating a direct role of CETP in accelerating tissue CE uptake independent of HDL particle origin. However, CETP expression does not alter hepatic VLDL-cholesterol/TG output or biliary lipid/fecal bile acid excretion.\",\n      \"method\": \"Radiolabeled HDL-CE kinetic studies in CETP transgenic vs. non-transgenic mice; hepatic VLDL secretion rate measurements; biliary lipid and fecal bile acid assays\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo isotopic kinetic studies with multiple tissue readouts and mechanistic controls\",\n      \"pmids\": [\"16806230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CETP expression in transgenic mice delays postprandial plasma clearance of triglyceride-rich lipoproteins by two mechanisms: (1) transferring TG to HDL and enriching remnant particles with CE, making them less susceptible to LPL-mediated lipolysis; and (2) reducing LPL expression and activity (~50% reduction in post-heparin plasma LPL activity and ~39% reduction in adipose LPL mRNA).\",\n      \"method\": \"Oral fat load postprandial TG curves; double-labeled chylomicron-like emulsion kinetics; VLDL secretion assay; post-heparin LPL activity; adipose LPL mRNA; CETP-Tg vs. non-Tg mice\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo transgenic model with multiple orthogonal mechanistic readouts (kinetics, enzyme activity, gene expression)\",\n      \"pmids\": [\"19191759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CETP polymorphisms affecting mRNA splicing have functional consequences: an alternatively spliced isoform lacking exon 9 (Δ9) prevents CETP secretion in a dominant-negative manner. rs9930761 (intron 8) alters a key splicing branch point nucleotide and rs5883 (exon 9) alters an exonic splicing enhancer sequence, together increasing Δ9 isoform formation (10–48% of total CETP mRNA in human livers), independently raising HDL-C and influencing cardiovascular risk.\",\n      \"method\": \"Allelic CETP mRNA expression in 56 human livers; splice isoform measurements; SNP genotyping; functional association in Whitehall II (n=4745) and INVEST-GENE cohorts\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct human liver mRNA splicing data with mechanistic SNP-to-function mapping, replicated in two clinical cohorts\",\n      \"pmids\": [\"22403620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Novel alternatively spliced CETP isoforms (skipping exon 9 sequences with insertion of Alu-derived in-frame exons) are not efficiently secreted and co-expression of them inhibits wild-type CETP secretion in a dominant-negative manner. Expression of all CETP variants (including wild-type) induces ER stress responses, suggesting CETP plays a role in modulating ER stress independent of its lipid transfer activity.\",\n      \"method\": \"Cell expression studies of splice variants; Western blot of secretion efficiency; ER stress gene induction assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct cell-based secretion and ER stress assays; single lab\",\n      \"pmids\": [\"18509195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CETP variants found in Asian individuals (Y332, Q296, G442) are secreted less efficiently than wild-type protein but retain significant cholesteryl ester transfer activity in vitro, while P151 variant is not secreted and shows no transfer activity. A null splice variant causing protein truncation was found in Europeans on the same haplotype as in Asians, suggesting common origin.\",\n      \"method\": \"In vitro secretion efficiency by Western blot; fluorescent substrate CE transfer activity assay; exon resequencing\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution of secretion and enzymatic activity for multiple variants; single lab\",\n      \"pmids\": [\"18468607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Novel CETP loss-of-function mutations (Q165X, R268X introducing premature stop codons; IVS15+2T>C abolishing a splice donor site) cause reduced CETP activity (38–60% reduction) and primary hyperalphalipoproteinemia in Italian subjects. Minigene analysis in COS-1 cells showed the IVS15+2T>C mutation causes exon 14–16 direct joining, producing a truncated 435-amino acid peptide.\",\n      \"method\": \"CETP gene sequencing; minigene splicing assay in COS-1 cells; plasma CETP activity assay\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct functional validation of mutations via minigene assay plus enzymatic activity measurement\",\n      \"pmids\": [\"18926541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CETP expression in macrophages and endothelial cells lowers TLR4 expression and NF-κB activation, reducing LPS uptake, TLR4-dependent signaling, and IL-6 secretion. In transgenic mice, CETP expression improves survival in polymicrobial sepsis (CLP model) and reduces plasma IL-6. Recombinant human CETP added to wild-type macrophages recapitulates these effects.\",\n      \"method\": \"CETP transgenic mice CLP sepsis model; macrophage LPS stimulation with/without recombinant CETP; TLR4/NF-κB/IL-6 measurements; survival analysis\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model plus in vitro recombinant protein experiments; single lab\",\n      \"pmids\": [\"27293313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CETP expression in endothelial cells generates vascular oxidative stress and endothelial dysfunction. CETP transgenic mice show impaired acetylcholine-induced endothelium-dependent relaxation, increased superoxide and H2O2 production in aortas, and enhanced eNOS activation. Silencing CETP in human aortic endothelial cells reduces mitochondrial and NOX2-derived ROS, decreases ER stress markers, lowers TNFα, ICAM-1, and VCAM-1 expression, and reduces monocyte adhesion.\",\n      \"method\": \"Aortic ring relaxation assay in CETP transgenic mice; ROS measurement; eNOS activation assay; CETP siRNA knockdown in human endothelial cells; ER stress marker analysis; monocyte adhesion assay\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model plus in vitro siRNA knockdown with multiple orthogonal mechanistic readouts; single lab\",\n      \"pmids\": [\"33430172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CETP expression in macrophages reduces mitochondrial superoxide and H2O2 production, increases maximal mitochondrial respiration, promotes mitochondrial network elongation (increased mitofusin-2 and OPA1 expression), attenuates pro-inflammatory gene expression and phagocytic activity, reduces unesterified cholesterol accumulation under basal conditions and after oxidized-LDL exposure, and enhances HDL-mediated cholesterol efflux. CETP knockdown in THP1 cells increased unesterified cholesterol and abolished mitofusin-2 and TNFα effects.\",\n      \"method\": \"CETP transgenic mouse macrophages vs. non-transgenic; mitochondrial ROS/respiration assays; gene expression; CETP knockdown in THP1 cells; cholesterol efflux assay\",\n      \"journal\": \"Antioxidants (Basel, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic model plus siRNA knockdown in human cells; multiple orthogonal readouts; single lab\",\n      \"pmids\": [\"36139808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HDL isolated from carriers of CETP null mutations (genetic CETP deficiency) is significantly less effective than control HDL in stimulating nitric oxide (NO) production in endothelial cells due to reduced eNOS-activating capacity, likely because of reduced sphingosine-1-phosphate (S1P) content in structurally altered HDL particles. However, CETP-deficient HDL retains the ability to downregulate cytokine-induced VCAM-1 expression.\",\n      \"method\": \"HDL isolation from CETP-deficient human subjects; eNOS activation and NO production assays in cultured endothelial cells; VCAM-1 expression assays; S1P content analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with human genetic CETP-deficient HDL; single study\",\n      \"pmids\": [\"24830642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Using in vivo stable isotope tracer studies and compartmental modeling, CETP is secreted mainly in alpha1 and alpha2 HDL subfractions and remains in these sizes during circulation (unlike PLTP which transfers between HDL sizes). CETP metabolism on multiple HDL sizes was resolved by targeted mass spectrometry on the Orbitrap Fusion Lumos.\",\n      \"method\": \"In vivo stable isotope tracer kinetics; targeted mass spectrometry (Orbitrap Fusion Lumos); compartmental modeling of CETP on HDL subfractions from 6 participants\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo tracer kinetics with MS-based compartmental modeling; small n but rigorous methodology\",\n      \"pmids\": [\"33351780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Atorvastatin increases HDL-cholesterol in CETP-expressing (E3L.CETP) but not in non-CETP-expressing (E3L) mice by reducing hepatic CETP mRNA expression (-57%), lowering total plasma CETP mass (-29%) and CE transfer activity (-36%), thereby reducing CETP-dependent transfer of cholesterol from HDL to (V)LDL.\",\n      \"method\": \"Atorvastatin treatment of E3L and E3L.CETP transgenic mice; hepatic CETP mRNA quantification; plasma CETP mass and activity assays; lipoprotein cholesterol analysis\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — controlled transgenic animal experiment with multiple biochemical readouts; single lab\",\n      \"pmids\": [\"17868678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Anacetrapib reduces (V)LDL cholesterol by two CETP-related and CETP-independent mechanisms: (1) inhibition of CETP activity producing remodeled VLDL particles more susceptible to hepatic uptake; and (2) CETP-independent downregulation of hepatic PCSK9 expression (-28%), resulting in reduced plasma PCSK9 (-47%), increased hepatic LDL receptor content (+64%), and accelerated VLDL clearance. The PCSK9-lowering effect was confirmed in E3L mice lacking CETP.\",\n      \"method\": \"Anacetrapib treatment in E3L.CETP and E3L (non-CETP) transgenic mice; liver microarray; hepatic Pcsk9 and LDLr expression; plasma PCSK9 measurement; [14C]cholesteryl-oleate VLDL-mimicking particle clearance assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic dissection using CETP-expressing vs. CETP-null mice with multiple biochemical and in vivo clearance assays\",\n      \"pmids\": [\"26342106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CETP inhibition with anacetrapib in high-fat-diet-fed CETP transgenic mice improves HDL functionality (reverse cholesterol transport, antioxidative capacity) but worsens anti-inflammatory HDL capacity, markedly alters the HDL proteome, and causes hepatic triglyceride accumulation and insulin resistance, revealing context-dependent (obese vs. lean) effects of CETP inhibition.\",\n      \"method\": \"Anacetrapib treatment in chow- and HFD-fed CETP transgenic mice; reverse cholesterol transport assay; HDL antioxidative and anti-inflammatory capacity assays; HDL proteomics; liver TG measurement; insulin resistance assessment\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal HDL functional assays in transgenic mice; single lab\",\n      \"pmids\": [\"30213825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Novel CETP inhibitor K-312 decreases PCSK9 expression in human primary hepatocytes and HepG2 cells by a CETP-independent mechanism: it reduces active forms of SREBP-1 and SREBP-2 and decreases their occupancy on the sterol regulatory element of the PCSK9 promoter, as demonstrated by chromatin immunoprecipitation. CETP siRNA silencing did not abolish PCSK9 suppression by K-312.\",\n      \"method\": \"In vitro human primary hepatocyte and HepG2 cell assays; CETP siRNA knockdown; SREBP Western blot; chromatin immunoprecipitation (ChIP); PCSK9 protein measurement in rabbit blood by mass spectrometry\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP assay plus siRNA knockdown controls establishing CETP-independent mechanism; single lab\",\n      \"pmids\": [\"26015437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Apolipoprotein CI (apoCI) is a potent inhibitor of CETP specific activity in plasma. However, apoCI overexpression in CETP transgenic mice paradoxically increases total plasma CE transfer activity because the resulting hyperlipidemia activates LXR, upregulating hepatic CETP mRNA ~4-fold and CETP mass ~3-fold, demonstrating that LXR-mediated CETP gene induction can override pharmacological inhibition of specific CETP activity.\",\n      \"method\": \"CETPTg/apoCITg double transgenic mice; plasma CE transfer activity assays; hepatic CETP mRNA measurement; LXR-target gene expression (ABCG5, SREBP-1c)\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with enzymatic activity and gene expression readouts; single lab\",\n      \"pmids\": [\"15339254\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CETP is a plasma glycoprotein (secreted primarily from liver and adipose tissue) that mediates bidirectional transfer of cholesteryl esters and triglycerides between HDL and apoB-containing lipoproteins (VLDL/LDL); its transcription is driven by LXRα/RXR via a DR4 promoter element in response to sterols; it preferentially acts on HDL3 (modulated by LTIP), delays TG-rich lipoprotein clearance partly by suppressing LPL, enhances hepatic HDL-CE uptake, and in endothelial cells and macrophages exerts direct effects on oxidative stress, ER homeostasis, and inflammatory signaling (TLR4/NF-κB pathway), while alternatively spliced Δ9 isoforms act as dominant-negative inhibitors of CETP secretion.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CETP is a secreted plasma glycoprotein that mediates the bidirectional transfer of cholesteryl esters and triglycerides between HDL and apoB-containing lipoproteins (VLDL/LDL), thereby serving as a central regulator of plasma lipoprotein remodeling, HDL metabolism, and reverse cholesterol transport. Transcription of CETP is driven by LXRα/RXR heterodimers binding a DR4 element in the promoter in response to sterols, with LXRα—not LXRβ—being the essential subtype [PMID:10683381, PMID:20494359]; adipose tissue and liver are the principal sources of circulating CETP [PMID:16751623, PMID:9712344]. Functionally, CETP accelerates hepatic HDL-cholesteryl ester uptake, delays postprandial triglyceride-rich lipoprotein clearance in part by suppressing LPL expression, and preferentially acts on HDL3 through modulation by lipid transfer inhibitor protein (LTIP) [PMID:16806230, PMID:19191759, PMID:12907677]. Loss-of-function mutations (including premature stop codons and splice-site variants) cause primary hyperalphalipoproteinemia, and alternatively spliced Δ9 isoforms act as dominant-negative inhibitors of CETP secretion, linking common intronic/exonic polymorphisms to elevated HDL-C [PMID:18926541, PMID:22403620].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing that adipose tissue is a physiologically important source of plasma CETP resolved where the circulating protein originates beyond the liver.\",\n      \"evidence\": \"Correlation of adipose CETP mRNA with plasma CETP concentration (r=0.85) in two human cohorts using ex vivo organ culture\",\n      \"pmids\": [\"9712344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Correlational design; no causal manipulation of adipose CETP in humans\", \"Relative hepatic vs. adipose contribution not quantified in the same subjects\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of the DR4 element and LXR/RXR-dependent sterol-responsive transcription of CETP established the core transcriptional control mechanism linking dietary cholesterol to plasma CETP levels.\",\n      \"evidence\": \"Promoter-luciferase mutagenesis, EMSA, and transgenic mice with normal vs. mutated CETP promoter\",\n      \"pmids\": [\"10683381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other transcription factors acting on the CETP promoter not characterized\", \"Tissue-specific differences in LXR-dependent regulation not resolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that LTIP modulates CETP substrate specificity—stimulating CE transfer from HDL3 while suppressing it from HDL2—explained the observed in vivo HDL-subclass selectivity of CETP.\",\n      \"evidence\": \"Reconstituted in vitro CE transfer assays with radiolabeled substrates and multiple lipoprotein fractions\",\n      \"pmids\": [\"12907677\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of LTIP modulation not tested in animal models\", \"Structural basis of LTIP–CETP interaction unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The finding that apoCI-induced hyperlipidemia overrides apoCI's direct CETP inhibition via LXR-mediated CETP gene induction revealed a feedback loop in which substrate accumulation amplifies CETP expression.\",\n      \"evidence\": \"Double-transgenic (CETPTg/apoCITg) mice with hepatic gene expression and plasma CE transfer activity measurements\",\n      \"pmids\": [\"15339254\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise LXR ligand(s) generated by apoCI-induced hyperlipidemia not identified\", \"Relevance to human apoCI–CETP axis not confirmed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Adipose-specific CETP transgenic mice proved causally that adipose-derived CETP contributes substantially to circulating CETP mass and produces systemic lipoprotein remodeling (reduced HDL-C, increased non-HDL cholesterol).\",\n      \"evidence\": \"Adipose-tissue-specific transgenic mouse model with plasma CETP mass/activity and lipoprotein profiling\",\n      \"pmids\": [\"16751623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of adipose vs. hepatic CETP in humans remains unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Radiolabeled HDL-CE kinetic studies in CETP transgenic mice demonstrated that CETP accelerates hepatic (and other tissue) CE uptake without altering VLDL secretion or biliary excretion, defining the catabolic arm of CETP's effect on HDL.\",\n      \"evidence\": \"In vivo isotopic HDL-CE kinetics in CETP transgenic vs. non-transgenic mice with tissue uptake measurements\",\n      \"pmids\": [\"16806230\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor(s) mediating enhanced hepatic CE uptake in the presence of CETP not identified\", \"Biliary cholesterol secretion pathway may differ in humans\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery and functional characterization of alternatively spliced CETP isoforms (Δ9 and Alu-exon insertions) that are secretion-incompetent and act as dominant-negative inhibitors of wild-type CETP secretion revealed a post-transcriptional layer of CETP regulation and linked CETP expression to ER stress.\",\n      \"evidence\": \"Cell-based secretion assays, Western blot, ER stress gene induction; variant activity reconstitution; human liver mRNA quantification\",\n      \"pmids\": [\"18509195\", \"22403620\", \"18468607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological triggers that shift the splicing ratio in vivo are unknown\", \"ER stress induction mechanism by CETP variants not elucidated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of loss-of-function CETP mutations (Q165X, R268X, IVS15+2T>C) causing hyperalphalipoproteinemia in Italian subjects, with functional validation by minigene assays, established that CETP deficiency is a Mendelian cause of elevated HDL-C in Europeans as well as Asians.\",\n      \"evidence\": \"CETP gene sequencing, minigene splicing assay in COS-1 cells, plasma CETP activity measurement\",\n      \"pmids\": [\"18926541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cardiovascular outcome in European CETP-deficient subjects not resolved\", \"Compound heterozygote phenotypes not characterized\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showing that CETP delays postprandial TG-rich lipoprotein clearance both by remodeling remnant composition and by suppressing LPL expression/activity explained CETP's proatherogenic role beyond HDL lowering.\",\n      \"evidence\": \"Oral fat load kinetics, double-labeled chylomicron-like emulsion clearance, post-heparin LPL activity, and adipose LPL mRNA in CETP transgenic mice\",\n      \"pmids\": [\"19191759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CETP reduces LPL transcription is not defined\", \"Human postprandial studies with CETP inhibitors needed for translation\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Establishing that LXRα—not LXRβ—is the obligate mediator of sterol-responsive CETP transcription refined the transcriptional model and identified a druggable regulatory node.\",\n      \"evidence\": \"siRNA knockdown in HepG2 cells plus LXRα-knockout CETP transgenic mice\",\n      \"pmids\": [\"20494359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LXRα-selective agonists differentially regulate CETP in human liver is untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Dissection of anacetrapib's dual mechanism—CETP-dependent VLDL remodeling plus CETP-independent PCSK9/LDL-receptor regulation—revealed that pharmacological CETP inhibitors have off-target effects on hepatic cholesterol homeostasis.\",\n      \"evidence\": \"Anacetrapib treatment in E3L.CETP and E3L (non-CETP) transgenic mice; liver microarray; ChIP for SREBP on PCSK9 promoter; VLDL clearance assays\",\n      \"pmids\": [\"26342106\", \"26015437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CETP-independent PCSK9-lowering mechanism of anacetrapib not fully resolved at the molecular level\", \"Translation to human hepatocytes awaits confirmation\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that CETP lowers TLR4 expression and NF-κB activation in macrophages and endothelial cells, improving sepsis survival, uncovered a direct anti-inflammatory function independent of lipoprotein remodeling.\",\n      \"evidence\": \"CETP transgenic mice in CLP sepsis model; recombinant CETP added to macrophages; TLR4/NF-κB/IL-6 measurements\",\n      \"pmids\": [\"27293313\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which CETP reduces TLR4 expression is unknown\", \"Single-lab finding; not independently replicated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"In vivo stable-isotope tracer kinetics resolved that CETP is secreted into and circulates predominantly on alpha1 and alpha2 HDL subfractions, providing a biophysical framework for its site of action in lipoprotein remodeling.\",\n      \"evidence\": \"Stable isotope tracer kinetics with targeted mass spectrometry and compartmental modeling in 6 human participants\",\n      \"pmids\": [\"33351780\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small sample size (n=6)\", \"Whether CETP's HDL subfraction distribution changes in dyslipidemia is unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing that macrophage CETP expression reduces mitochondrial ROS, promotes mitochondrial fusion (via mitofusin-2/OPA1), and enhances HDL-mediated cholesterol efflux extended CETP's intracellular functions to mitochondrial dynamics and oxidative stress regulation.\",\n      \"evidence\": \"CETP transgenic mouse macrophages and CETP-knockdown THP1 cells; mitochondrial respiration/ROS assays; cholesterol efflux; gene expression\",\n      \"pmids\": [\"36139808\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking CETP to mitofusin-2 induction unknown\", \"Single-lab finding; no independent replication\", \"Physiological relevance of macrophage-endogenous CETP expression in humans unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CETP's interaction with specific HDL subclasses and LTIP, the molecular mechanism by which CETP suppresses LPL and TLR4 expression, and whether the intracellular (ER stress, mitochondrial) functions of CETP are physiologically significant in humans.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of CETP bound to HDL or LTIP\", \"Mechanism of LPL transcriptional suppression by CETP undefined\", \"Intracellular CETP functions tested only in transgenic models and cell lines\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 5, 6]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [2, 5, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 4, 5, 15]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [8, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [2, 5, 6, 17]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [2, 5, 6, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"LXRA\",\n      \"RXRA\",\n      \"APOC1\",\n      \"LPL\",\n      \"APOA1\",\n      \"MFN2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}